290 related articles for article (PubMed ID: 26228632)
1. Innate lymphoid cells in graft-versus-host disease.
Konya V; Mjösberg J
Am J Transplant; 2015 Nov; 15(11):2795-801. PubMed ID: 26228632
[TBL] [Abstract][Full Text] [Related]
2. Helper Innate Lymphoid Cells in Allogenic Hematopoietic Stem Cell Transplantation and Graft Versus Host Disease.
Quatrini L; Tumino N; Moretta F; Besi F; Vacca P; Moretta L
Front Immunol; 2020; 11():582098. PubMed ID: 33101308
[TBL] [Abstract][Full Text] [Related]
3. Human ectoenzyme-expressing ILC3: immunosuppressive innate cells that are depleted in graft-versus-host disease.
Hazenberg MD; Haverkate NJE; van Lier YF; Spits H; Krabbendam L; Bemelman WA; Buskens CJ; Blom B; Shikhagaie MM
Blood Adv; 2019 Nov; 3(22):3650-3660. PubMed ID: 31751473
[TBL] [Abstract][Full Text] [Related]
4. Presence of innate lymphoid cells in allogeneic hematopoietic grafts correlates with reduced graft-versus-host disease.
Kroeze A; van Hoeven V; Verheij MW; Turksma AW; Weterings N; van Gassen S; Zeerleder SS; Blom B; Voermans C; Hazenberg MD
Cytotherapy; 2022 Mar; 24(3):302-310. PubMed ID: 35058143
[TBL] [Abstract][Full Text] [Related]
5. Group 3 innate lymphoid cells in tissue damage and graft-versus-host disease pathogenesis.
Karrich JJ; Cupedo T
Curr Opin Hematol; 2016 Jul; 23(4):410-5. PubMed ID: 27135976
[TBL] [Abstract][Full Text] [Related]
6. Innate lymphoid cell recovery and occurrence of GvHD after hematopoietic stem cell transplantation.
Piperoglou C; Larid G; Vallentin B; Balligand L; Crinier A; Banzet N; Farnarier C; Gomez-Massa E; Adalia AC; ; Michel G; Galambrun C; Barlogis V; Vivier E; Vély F
J Leukoc Biol; 2022 Jan; 111(1):161-172. PubMed ID: 33847423
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Lymphoid tissue inducer-A divergent member of the ILC family.
Zhong C; Zheng M; Zhu J
Cytokine Growth Factor Rev; 2018 Aug; 42():5-12. PubMed ID: 29454785
[TBL] [Abstract][Full Text] [Related]
9. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
10. Targeting Inflammatory T Helper Cells
Buchele V; Abendroth B; Büttner-Herold M; Vogler T; Rothamer J; Ghimire S; Ullrich E; Holler E; Neurath MF; Hildner K
Front Immunol; 2018; 9():1138. PubMed ID: 29910804
[TBL] [Abstract][Full Text] [Related]
11. [Innate lymphoid cells].
Crinier A; Viant C; Girard-Madoux M; Vivier É
Med Sci (Paris); 2017 May; 33(5):534-542. PubMed ID: 28612730
[TBL] [Abstract][Full Text] [Related]
12. Advances in understanding the pathogenesis of graft-versus-host disease.
Magenau J; Runaas L; Reddy P
Br J Haematol; 2016 Apr; 173(2):190-205. PubMed ID: 27019012
[TBL] [Abstract][Full Text] [Related]
13. Source of hematopoietic progenitor cells determines their capacity to generate innate lymphoid cells ex vivo.
Omar SZ; van Hoeven V; Haverkate NJE; Van der Meer JMR; Voermans C; Blom B; Hazenberg MD
Cytotherapy; 2024 Apr; 26(4):334-339. PubMed ID: 38363249
[TBL] [Abstract][Full Text] [Related]
14. Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Fu J; Heinrichs J; Yu XZ
Arch Immunol Ther Exp (Warsz); 2014 Aug; 62(4):277-301. PubMed ID: 24699629
[TBL] [Abstract][Full Text] [Related]
15. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.
Jiang H; Fu D; Bidgoli A; Paczesny S
Front Immunol; 2021; 12():761448. PubMed ID: 34675938
[TBL] [Abstract][Full Text] [Related]
16. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.
Dander E; Balduzzi A; Zappa G; Lucchini G; Perseghin P; Andrè V; Todisco E; Rahal D; Migliavacca M; Longoni D; Solinas G; Villa A; Berti E; Mina PD; Parma M; Allavena P; Biagi E; Rovelli A; Biondi A; D'Amico G
Transplantation; 2009 Dec; 88(11):1261-72. PubMed ID: 19996925
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
19. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
20. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
Front Immunol; 2019; 10():1997. PubMed ID: 31507601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
